[go: up one dir, main page]

MX2015015662A - Receptor quimérico de antígeno especifico para cd19 y sus usos. - Google Patents

Receptor quimérico de antígeno especifico para cd19 y sus usos.

Info

Publication number
MX2015015662A
MX2015015662A MX2015015662A MX2015015662A MX2015015662A MX 2015015662 A MX2015015662 A MX 2015015662A MX 2015015662 A MX2015015662 A MX 2015015662A MX 2015015662 A MX2015015662 A MX 2015015662A MX 2015015662 A MX2015015662 A MX 2015015662A
Authority
MX
Mexico
Prior art keywords
present
car
relates
chemeric
receiver
Prior art date
Application number
MX2015015662A
Other languages
English (en)
Other versions
MX374681B (es
Inventor
Galetto Roman
Scharenberg Andrew
Smith Julianne
SCHIFFER-MANNIOUI Cècile
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51897790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015015662(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/040766 external-priority patent/WO2013176916A1/en
Application filed by Cellectis filed Critical Cellectis
Publication of MX2015015662A publication Critical patent/MX2015015662A/es
Publication of MX374681B publication Critical patent/MX374681B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

Receptores de antígenos quiméricos (CAR). Los CAR tienen la capacidad de redirigir la especificidad y reactividad de la célula inmune hacia un blanco seleccionado haciendo uso de las propiedades de dominio de unión a ligando. En particular, la presente invención se relaciona con un receptor quimérico de antígeno en donde la unión a ligando extracelular es un scFv derivado de un anticuerpo monoclonal contra CD19, preferentemente 4G7. La presente invención también se relaciona con polinucleótidos, vectores que codifican para los CAR y células aisladas que expresan el CAR en su superficie. La presente invención también se relaciona con métodos para diseñar células inmunes que expresan 4G7-CAR en su superficie que confiere un estado "activado" prolongado en la célula transducida. La presente invención es particularmente útil para el tratamiento de linfomas de células B y leucemia.
MX2015015662A 2013-05-13 2014-05-12 Receptor quimérico de antígeno específico para cd19 y sus usos. MX374681B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2013/040766 WO2013176916A1 (en) 2012-05-25 2013-05-13 Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
PCT/US2013/040755 WO2013176915A1 (en) 2012-05-25 2013-05-13 Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US13/892,805 US11603539B2 (en) 2012-05-25 2013-05-13 Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
US201361888259P 2013-10-08 2013-10-08
PCT/EP2014/059662 WO2014184143A1 (en) 2013-05-13 2014-05-12 Cd19 specific chimeric antigen receptor and uses thereof

Publications (2)

Publication Number Publication Date
MX2015015662A true MX2015015662A (es) 2016-09-16
MX374681B MX374681B (es) 2025-03-06

Family

ID=51897790

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015662A MX374681B (es) 2013-05-13 2014-05-12 Receptor quimérico de antígeno específico para cd19 y sus usos.

Country Status (29)

Country Link
US (2) US20210000869A9 (es)
EP (3) EP2997141B1 (es)
JP (2) JP6491643B2 (es)
KR (1) KR102248157B1 (es)
CN (2) CN109897100A (es)
AU (2) AU2014267436B2 (es)
BR (1) BR112015028387B1 (es)
CA (1) CA2911292C (es)
DK (1) DK3546572T3 (es)
EA (2) EA201990575A3 (es)
ES (2) ES2978123T3 (es)
FI (2) FI3546572T3 (es)
HR (2) HRP20240576T1 (es)
HU (2) HUE060901T2 (es)
LT (2) LT3546572T (es)
MA (1) MA38630B2 (es)
MX (1) MX374681B (es)
MY (1) MY172897A (es)
PH (1) PH12015502479B1 (es)
PL (2) PL3546572T3 (es)
PT (2) PT3546572T (es)
RS (2) RS63798B1 (es)
RU (1) RU2727447C2 (es)
SA (1) SA515370135B1 (es)
SG (2) SG10201708896WA (es)
SI (2) SI3546572T1 (es)
TW (1) TWI636992B (es)
UA (1) UA118106C2 (es)
WO (1) WO2014184143A1 (es)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN111676196A (zh) 2012-05-25 2020-09-18 塞勒克提斯公司 工程化异体和免疫抑制耐受性t细胞的方法
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
DK3066201T3 (en) 2013-11-07 2018-06-06 Editas Medicine Inc CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
CA2934436A1 (en) * 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
EP4079847A1 (en) 2014-07-30 2022-10-26 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
US20170354681A1 (en) * 2014-10-24 2017-12-14 Bcrt Holding Bv T cell-based immunotherapeutics
CA2969384A1 (en) * 2014-12-17 2016-06-23 Cellectis Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
EP3237442B1 (en) 2014-12-24 2019-07-10 UCL Business PLC Cell
EP3250609A4 (en) 2015-01-26 2018-07-11 The University of Chicago Il13ra alpha 2 binding agents and use thereof in cancer treatment
US20180170992A1 (en) 2015-01-26 2018-06-21 The University Of Chicago CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
DK3250606T3 (da) 2015-01-26 2021-01-04 Cellectis ANTI-CLL1-specifikke enkeltkædede kimære antigenreceptorer (SCCARS) til cancerimmunterapi
EP4091616A1 (en) 2015-02-27 2022-11-23 iCell Gene Therapeutics LLC Chimeric antigen receptors (car) targeting hematologic malignancies, compositions and methods of use thereof
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
ES2807591T3 (es) 2015-04-13 2021-02-23 Pfizer Receptores de antígeno quimérico dirigidos a antígeno de maduración de células B
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
EA202090931A3 (ru) 2015-05-18 2020-10-30 Тср2 Терапьютикс Инк. Композиции и способы перепрограммирования tcr с помощью гибридных белков
CN104829733B (zh) * 2015-05-25 2018-06-05 广州百暨基因科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
EP3313872A4 (en) 2015-06-25 2019-03-20 iCell Gene Therapeutics LLC CHIMERIC ANTIGEN RECEPTORS (CARS) COMPOSITIONS AND METHOD FOR USE THEREOF
JP7033453B2 (ja) * 2015-06-30 2022-03-10 セレクティス 特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法
EP3334442B1 (en) 2015-08-11 2024-12-18 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
WO2017044464A1 (en) * 2015-09-11 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Biologically relevant orthogonal cytokine/receptor pairs
KR20180083313A (ko) 2015-09-24 2018-07-20 에이비비트로, 엘엘씨 Hiv 항체 조성물 및 사용 방법
JP7067793B2 (ja) 2015-10-23 2022-05-16 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸塩基編集因子およびその使用
AU2016343805A1 (en) 2015-10-30 2018-06-07 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
US10508143B1 (en) 2015-10-30 2019-12-17 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
GB201519900D0 (en) * 2015-11-11 2015-12-23 Ucl Business Plc Chimeric antigen receptor
MY192474A (en) 2016-01-21 2022-08-23 Pfizer Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
CN107298715B (zh) 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CN107446051B9 (zh) * 2016-05-31 2019-02-22 上海恒润达生生物科技有限公司 靶向cd19的嵌合抗原受体及其用途
US20200283534A1 (en) 2016-06-24 2020-09-10 iCell Gene Therapeuticics LLC CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
PL240585B1 (pl) * 2016-07-18 2022-05-02 Helix Biopharma Corp Chimeryczny receptor antygenowy (CAR), komórki immunologiczne zawierające CAR oraz kompozycja farmaceutyczna je zawierająca do leczenia nowotworów
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
IL264565B2 (en) 2016-08-03 2024-07-01 Harvard College Adenosine nucleobase editors and uses thereof
EP3497214B1 (en) 2016-08-09 2023-06-28 President and Fellows of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN109789164B (zh) * 2016-08-30 2023-04-28 亘喜生物科技（上海）有限公司 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体
CN109715199A (zh) 2016-09-14 2019-05-03 詹森生物科技公司 包含bcma特异性iii型纤连蛋白结构域的嵌合抗原受体及其用途
CN108699163B (zh) * 2016-09-28 2021-11-19 阿思科力(苏州)生物科技有限公司 一种多基因重组嵌合抗原受体分子及其应用
CN112280796A (zh) 2016-10-07 2021-01-29 T细胞受体治疗公司 使用融合蛋白进行t细胞受体重编程的组合物和方法
JP2020500031A (ja) * 2016-10-11 2020-01-09 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊抗体及び開裂酵素の使用
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP7778468B2 (ja) 2016-11-22 2025-12-02 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
EP3592777A1 (en) 2017-03-10 2020-01-15 President and Fellows of Harvard College Cytosine to guanine base editor
SG11201908658TA (en) 2017-03-23 2019-10-30 Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
AU2018251150B2 (en) 2017-04-13 2024-05-09 Albert-Ludwigs-Universität Freiburg New sequence specific reagents targeting CCR5 in primary hematopoietic cells
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2018222935A1 (en) 2017-06-02 2018-12-06 Pfizer Inc. Chimeric antigen receptors targeting flt3
US12275787B2 (en) 2017-06-21 2025-04-15 Icell Gene Therapeutics Llc Chimeric antigen receptors (CARs), compositions and methods thereof
US12144825B2 (en) 2017-06-30 2024-11-19 Cellectis Cellular immunotherapy for repetitive administration
IL271982B2 (en) 2017-07-17 2025-02-01 Janssen Biotech Inc Antigen binding regions against fibronectin type III sites and methods of using them
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
BR112020008428A2 (pt) * 2017-10-31 2020-12-01 Allogene Therapeutics, Inc. métodos e composições para dosagem de células t com receptor de antígeno quimérico alogênicas
US11326156B2 (en) 2017-11-01 2022-05-10 Allogene Therapeutics, Inc. Modified caspase-9 polypeptides and methods of use thereof
WO2019106163A1 (en) 2017-12-01 2019-06-06 Cellectis Reprogramming of genetically engineered primary immune cells
JP7089806B2 (ja) 2017-12-06 2022-06-23 アブクロン・インコーポレイテッド 悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
EP3724214A4 (en) 2017-12-15 2021-09-01 The Broad Institute Inc. SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
TWI800522B (zh) * 2017-12-23 2023-05-01 宇越生醫科技股份有限公司 醫藥重組受體組成物及方法
WO2019152705A1 (en) 2018-02-01 2019-08-08 Pfizer Inc. Antibodies specific for cd70 and their uses
PE20252242A1 (es) 2018-02-01 2025-09-15 Pfizer Receptores de antigeno quimericos dirigidos a cd70
RU2020128440A (ru) 2018-02-28 2022-03-28 Пфайзер Инк. Варианты il-15 и их применения
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020011706A1 (en) * 2018-07-09 2020-01-16 Oslo Universitetssykehus Hf Two chimeric antigen receptors specifically binding cd19 and igkappa
SG11202101773WA (en) 2018-08-29 2021-03-30 Nanjing Legend Biotech Co Ltd Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
AU2019336245A1 (en) 2018-09-07 2021-04-01 Beam Therapeutics Inc. Compositions and methods for delivering a nucleobase editing system
US12454694B2 (en) 2018-09-07 2025-10-28 Beam Therapeutics Inc. Compositions and methods for improving base editing
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2020109953A1 (en) 2018-11-30 2020-06-04 Janssen Biotech, Inc. Gamma delta t cells and uses thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
RU2742000C2 (ru) * 2019-03-13 2021-02-01 Общество С Ограниченной Ответственностью "Анабион" Выделенный альтернативный внутриклеточный сигнальный домен химерного антигенного рецептора и включающий его химерный антигенный рецептор
WO2020191246A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
AU2020257252A1 (en) * 2019-04-19 2021-10-14 Allogene Therapeutics, Inc. Antibodies against 4G7-derived chimeric antigen receptors
ES2961314T3 (es) 2019-04-26 2024-03-11 Allogene Therapeutics Inc Receptores quiméricos de antígeno resistentes a rituximab y usos de los mismos
KR20220069926A (ko) 2019-08-27 2022-05-27 얀센 바이오테크 인코포레이티드 키메라 항원 수용체 시스템 및 그의 용도
WO2021072328A1 (en) 2019-10-10 2021-04-15 The Broad Institute, Inc. Methods and compositions for prime editing rna
CN112079934B (zh) 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
AU2021232141A1 (en) 2020-03-03 2022-09-22 Janssen Biotech, Inc. ꝩδ T cells and uses thereof
KR20220150353A (ko) 2020-03-05 2022-11-10 네오티엑스 테라퓨틱스 엘티디. 면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물
GB2614813B (en) 2020-05-08 2025-05-07 Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
AU2021312871A1 (en) 2020-07-21 2023-02-09 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
US20220031751A1 (en) 2020-08-03 2022-02-03 Kyverna Therapeutics, Inc. Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same
EP4196231A1 (en) 2020-08-14 2023-06-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Chimeric antigen receptor t cells for treating autoimmunity
CN111944850B (zh) * 2020-08-28 2023-03-31 澳门大学 表达抗cd22嵌合抗原受体和pd-l1阻断蛋白的细胞的制备方法、表达载体及应用
AU2021401052A1 (en) 2020-12-18 2023-06-22 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
CA3208717A1 (en) * 2021-02-19 2022-08-25 Preet M. Chaudhary Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
WO2022234158A1 (es) * 2021-05-06 2022-11-10 Institut D'investigacions Biomèdiques August Pi I Sunyer (Idibaps) Terapia de células t con receptor de antígeno quimérico específico de cd19
WO2022266075A1 (en) 2021-06-14 2022-12-22 Caribou Biosciences, Inc. Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain
EP4502177A1 (en) 2022-03-24 2025-02-05 Nanjing Legend Biotech Co., Ltd. Method for preparing dna library and detecting retroviral integration site
WO2025051339A1 (en) 2023-09-05 2025-03-13 Tiber Biotech Srl SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR
EP4574838A1 (en) 2023-12-21 2025-06-25 Vilnius University Chimeric antigen receptor (car) with enhanced recruitment of signaling partners

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU4328801A (en) 2000-02-24 2001-09-03 Xcyte Therapies Inc Simultaneous stimulation and concentration of cells
EP1334188B1 (en) * 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
AU2007285976B2 (en) * 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
US20080131415A1 (en) * 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
ES2599172T3 (es) * 2007-10-19 2017-01-31 Seattle Genetics, Inc. Agentes de unión a CD19 y usos de éstos
WO2009091826A2 (en) * 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
ES2553421T3 (es) * 2008-08-26 2015-12-09 City Of Hope Método y composiciones para el funcionamiento potenciado del efector antitumoral de células T
WO2012050374A2 (en) * 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX2013008376A (es) 2011-01-18 2013-08-12 Univ Pennsylvania Composiciones y metodos para el tratamiento de cancer.
US20120245996A1 (en) 2011-03-22 2012-09-27 Jonathan Mendez System and method for intent-based content matching
SG193591A1 (en) * 2011-03-23 2013-10-30 Hutchinson Fred Cancer Res Method and compositions for cellular immunotherapy
SG194115A1 (en) 2011-04-05 2013-11-29 Cellectis Method for the generation of compact tale-nucleases and uses thereof
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
PH12014500247A1 (en) * 2011-07-29 2014-03-24 Univ Pennsylvania Switch costimulatory receptors
MX2014003176A (es) * 2011-09-16 2015-08-05 Univ Pennsylvania Celulas t diseñadas mediante arn para el tratamiento de cancer.
EA201491572A1 (ru) 2012-02-22 2014-12-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Композиции и способы получения устойчивой популяции t-клеток, используемых для лечения злокачественного новообразования

Also Published As

Publication number Publication date
CA2911292A1 (en) 2014-11-20
EP4364809A3 (en) 2024-07-24
LT3546572T (lt) 2024-05-27
MA38630A1 (fr) 2017-07-31
EA201501109A1 (ru) 2016-06-30
EP3546572B9 (en) 2024-06-26
CN105431532B (zh) 2021-04-06
FI3546572T3 (fi) 2024-05-06
AU2014267436A1 (en) 2015-11-12
BR112015028387A2 (pt) 2017-09-19
HRP20240576T1 (hr) 2024-07-19
EP3546572B1 (en) 2024-03-13
HRP20221393T1 (hr) 2023-01-06
JP6491643B2 (ja) 2019-04-03
PT3546572T (pt) 2024-05-08
KR102248157B1 (ko) 2021-05-03
EP4364809A2 (en) 2024-05-08
CA2911292C (en) 2023-01-03
PL3546572T3 (pl) 2024-07-22
ES2930431T3 (es) 2022-12-12
EA036200B1 (ru) 2020-10-14
RU2015153250A (ru) 2017-06-19
US20210000869A9 (en) 2021-01-07
PH12015502479B1 (en) 2019-11-27
UA118106C2 (uk) 2018-11-26
SI2997141T1 (sl) 2023-04-28
MA38630B2 (fr) 2021-08-31
FI2997141T3 (fi) 2022-12-15
DK3546572T3 (da) 2024-05-06
EP2997141A1 (en) 2016-03-23
SA515370135B1 (ar) 2020-12-14
AU2019201818A1 (en) 2019-04-04
RU2727447C2 (ru) 2020-07-21
ES2978123T3 (es) 2024-09-05
HUE067258T2 (hu) 2024-10-28
JP6854307B2 (ja) 2021-04-07
RS65484B1 (sr) 2024-05-31
HK1222679A1 (en) 2017-07-07
JP2016520074A (ja) 2016-07-11
PL2997141T3 (pl) 2023-02-06
PH12015502479A1 (en) 2016-02-22
US20240269178A1 (en) 2024-08-15
AU2019201818B2 (en) 2021-09-09
TWI636992B (zh) 2018-10-01
KR20160030480A (ko) 2016-03-18
HK1222678A1 (zh) 2017-07-07
AU2014267436B2 (en) 2019-07-04
JP2019122382A (ja) 2019-07-25
HUE060901T2 (hu) 2023-04-28
SI3546572T1 (sl) 2024-06-28
CN109897100A (zh) 2019-06-18
US20190209616A1 (en) 2019-07-11
PT2997141T (pt) 2022-11-23
EA201990575A2 (ru) 2019-07-31
NZ714044A (en) 2021-08-27
TW201502139A (zh) 2015-01-16
BR112015028387B1 (pt) 2023-04-11
WO2014184143A1 (en) 2014-11-20
EP3546572A1 (en) 2019-10-02
LT2997141T (lt) 2023-02-10
RS63798B1 (sr) 2022-12-30
MY172897A (en) 2019-12-13
MX374681B (es) 2025-03-06
CN105431532A (zh) 2016-03-23
EA201990575A3 (ru) 2019-11-29
EP2997141B1 (en) 2022-10-12
SG11201508805UA (en) 2015-11-27
SG10201708896WA (en) 2017-11-29

Similar Documents

Publication Publication Date Title
MX2015015662A (es) Receptor quimérico de antígeno especifico para cd19 y sus usos.
AR096274A1 (es) Receptor quimérico de antígeno específico para cd19 y sus usos
CA2929984C (en) A t cell or natural killer (nk) cell which co-expresses two chimeric antigen receptors (cars)
MX2020007021A (es) Receptor quimerico de antigeno anti-cd19 humanizado.
AR117685A1 (es) Antígeno quimérico y receptores de células t y métodos de uso
MX2020003046A (es) Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.
MX2016012855A (es) Receptores de antigeno quimerico especifico de cd33 para inmunoterapia de cancer.
EP4368704A3 (en) Cell
EP4491715A3 (en) Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
PH12018550163A1 (en) Chimeric antigen and t cell receptors and methods of use
MX2019001184A (es) Anticuerpos anti-idiotípicos y métodos relacionados.
CL2016002195A1 (es) Receptor antigénico quimérico car con dominios de unión a antígenos a la región constante del receptor de células t beta
MX374929B (es) RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
AR104718A1 (es) Receptores de antígenos quiméricos específicos de anti-gd3 para inmunoterapias contra el cáncer
MX2015008740A (es) Variantes de regiones fc de igg1 de humano y usos de las mismas.
MX2017003640A (es) Receptores antigenicos quimericos.
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
MX389021B (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MX387562B (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
WO2015092024A3 (en) Method of engineering multi-input signal sensitive t cell for immunotherapy
SA521430654B1 (ar) مستقبلات مولِّدات ضد خيميرية مقاومة للريتوكسيماب واستخداماتها
AR111131A1 (es) Receptores de antígenos quiméricos para melanoma y usos de estos
EA202090716A1 (ru) Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований

Legal Events

Date Code Title Description
FG Grant or registration